Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 2c

Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update

May 10, 2016 4:02 PM EDT

BURNABY, British Columbia, May 10, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended March 31, 2016 and provided a corporate update.

Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, Since the beginning of the year, we have made solid progress within both our partnered and proprietary programs. We have also added to our senior leadership team with key hires that augment our drug development expertise as we continue to pursue multiple therapeutic opportunities that fit well with our... More